Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
| Autor: | Sulkowski, Mark, Hezode, Christophe, Gerstoft, Jan, Vierling, John M, Mallolas, Josep, Pol, Stanislas, Kugelmas, Marcelo, Murillo, Abel, Weis, Nina, Nahass, Ronald, Shibolet, Oren, Serfaty, Lawrence, Bourliere, Marc, DeJesus, Edwin, Zuckerman, Eli, Dutko, Frank, Shaughnessy, Melissa, Hwang, Peggy, Howe, Anita Y M, Wahl, Janice, Robertson, Michael, Barr, Eliav, Haber, Barbara |
|---|---|
| Zdroj: | In The Lancet 21-27 March 2015 385(9973):1087-1097 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|